A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)
Por:
Perez-Garcia, J, Llombart-Cussac, A, Holgado, E, Curigliano, G, Miranda, E, Alonso-Romero, J, Bermejo, B, Calvo, L, Caranana, V, Sanchez, S, Cortes, M, Vazquez, R, Prat, A, Borrego, M, Sampayo, M, Segui, M, Soberino, J, Malfettone, A, Schmid, P and Cortes, J
Publicada:
1 feb 2020
Resumen:
Filiaciones:
Perez-Garcia, J:
QuironSalud Grp, Inst Oncol, IOB, Barcelona, Spain
Med Scientia Innovat Res MedSIR, Randolph, NJ USA
Med Scientia Innovat Res MedSIR, Barcelona, Spain
:
Med Scientia Innovat Res MedSIR, Randolph, NJ USA
Med Scientia Innovat Res MedSIR, Barcelona, Spain
FISABIO, Hosp Arnau Vilanova, Valencia, Spain
Holgado, E:
Med Scientia Innovat Res MedSIR, Randolph, NJ USA
Med Scientia Innovat Res MedSIR, Barcelona, Spain
Hosp Univ Ramon & Cajal, Madrid, Spain
Curigliano, G:
Univ Milan, European Inst Oncol IRCCS, Milan, Italy
Alonso-Romero, J:
Univ Virgen Arrixaca, Hosp Clin, Murcia, Spain
Bermejo, B:
Hosp Clin Valencia, Valencia, Spain
Calvo, L:
Chuac, La Coruna, Spain
:
Hosp Arnau Vilanova, Valencia, Spain
Sanchez, S:
Complejo Hosp Navarra, Pamplona, Spain
Cortes, M:
Hosp Univ Ramon & Cajal, Madrid, Spain
Vazquez, R:
MD Anderson Canc Ctr, Madrid, Spain
Prat, A:
Hosp Clin Barcelona, Barcelona, Spain
Hosp Univ Virgen Rocio, Seville, Spain
Sampayo, M:
Med Scientia Innovat Res MedSIR, Randolph, NJ USA
Med Scientia Innovat Res MedSIR, Barcelona, Spain
Segui, M:
Corp Sanit Sanit Parc Tauli, Sabadell, Spain
Soberino, J:
QuironSalud Grp, Inst Oncol, IOB, Barcelona, Spain
Schmid, P:
Queen Mary Univ London, Barts Canc Inst, London, England
Cortes, J:
Med Scientia Innovat Res MedSIR, Randolph, NJ USA
Med Scientia Innovat Res MedSIR, Barcelona, Spain
QuironSalud Grp, Inst Oncol, IOB, Madrid, Spain
VHIO, Barcelona, Spain
|